CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

Sling ropes in $123m for oral thyroid eye disease drug

Sling oral IGF-1R blockerTepezzaPositive
AI Analysis

Summary

Sling secured $123 million in funding to advance development of the first oral IGF-1R blocker for thyroid eye disease, positioning it as a competitor to Amgen's Tepezza.

Importance:6/10
Sentiment:
0.60
fundingoral formulationIGF-1R inhibitorthyroid eye diseasecompetitive threat
Related Companies

Read the original article

Published by Pharmaceutical Technology on September 16, 2026 3:51 PM

Read Original